Bridgefront Capital LLC Lowers Holdings in Edwards Lifesciences Corporation $EW

Bridgefront Capital LLC lowered its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 50.2% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,085 shares of the medical research company’s stock after selling 10,181 shares during the period. Bridgefront Capital LLC’s holdings in Edwards Lifesciences were worth $784,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in EW. Level Four Advisory Services LLC boosted its position in Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after buying an additional 119 shares during the period. Colonial Trust Co SC increased its position in shares of Edwards Lifesciences by 0.4% during the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after acquiring an additional 120 shares during the period. Howard Capital Management Inc. increased its position in shares of Edwards Lifesciences by 3.3% during the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after acquiring an additional 132 shares during the period. Empirical Finance LLC raised its stake in shares of Edwards Lifesciences by 0.6% in the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock valued at $1,668,000 after acquiring an additional 134 shares in the last quarter. Finally, Alpine Bank Wealth Management boosted its holdings in Edwards Lifesciences by 10.7% in the third quarter. Alpine Bank Wealth Management now owns 1,392 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 135 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $81.82 on Monday. The firm has a market capitalization of $47.52 billion, a PE ratio of 44.71, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93. The business’s fifty day moving average price is $82.41 and its 200 day moving average price is $81.58. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on EW. Piper Sandler reissued an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Truist Financial set a $89.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, February 11th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Finally, TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,897,284.92. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 61,718 shares of company stock worth $5,236,281 over the last 90 days. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.